Nanobiotix S.A. is a late-stage clinical biotechnology company specializing in physics-based nanomedicines to revolutionize cancer treatment. Headquartered in Paris, France, with offices in the United States, it pioneers nanotechnology that enhances radiotherapy's efficacy. The company's lead candidate, NBTXR3 (marketed as Hensify in Europe), consists of hafnium oxide nanoparticles injected directly into tumors. Upon activation by standard radiotherapy, these particles amplify radiation's destructive effect on cancer cells by generating free radicals, while sparing surrounding healthy tissues. Nanobiotix S.A. operates in the healthcare sector, focusing on biotechnology within the oncology field. Its NanoXray platform targets solid tumors across multiple indications, including soft tissue sarcoma (with European CE marking), head and neck cancer, hepatocellular carcinoma, rectal cancer, and others in Phase I/III trials globally. The company employs around 103 people and maintains partnerships, such as with Janssen (Johnson & Johnson) for co-development in head, neck, and lung cancers. Founded in 2003 as a spin-off from SUNY Buffalo research, Nanobiotix S.A. holds key patents and has received awards like the 2019 Prix Galien for its innovative radioenhancer approach, positioning it as a leader in nanomedicine for radiotherapy enhancement.